אנליסטים פרמצבטיים של Piper Sandler יקיימו שיחת ועידה כדי לדון במצב הנוכחי של לחץ דם ריאתי (PAH), סוג של לחץ דם גבוה שמשפיע על העורקים בריאות. הם ידונו בכיצד ההחלטה
אנליסטים פרמצבטיים של Piper Sandler יקיימו שיחת ועידה כדי לדון במצב הנוכחי של לחץ דם ריאתי (PAH), סוג של לחץ דם גבוה שמשפיע על העורקים בריאות. הם ידונו בכיצד ההחלטה
Pharmaceuticals Analysts discuss the Pulmonary Arterial Hypertension (PAH) landscape and how Merck’s (MRK) Sotatercept PDUFA impacts Gossamer Bio (GOSS) Seralutinib and Keros Therapeutics (KROS) KER-01 on an Analyst/Industry conference call
In a report released on March 27, Thomas Smith from Leerink Partners reiterated a Buy rating on Keros Therapeutics (KROS – Research Report), with a price target of $129.00. Thomas
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Argenx Se (ARGX – Research Report), Iridex (IRIX – Research Report) and Keros Therapeutics (KROS – Research Report).
Argenx Se (ARGX)
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Argenx Se today and set a price target of $484.00. The company’s shares closed last Tuesday at $397.57.
According to TipRanks.com, CFA is a 4-star analyst with an average return of
Argenx Se has an analyst consensus of Moderate Buy, with a price target consensus of $473.99, implying a 18.9% upside from current levels. In a report issued on March 13, Morgan Stanley also maintained a Buy rating on the stock with a $515.00 price target.
See the top stocks recommended by analysts >>
Iridex (IRIX)
Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Iridex today and set a price target of $2.00. The company’s shares closed last Tuesday at $2.51.
According to TipRanks.com, Stephan is a 4-star analyst with an average return of
Currently, the analyst consensus on Iridex is a Hold with an average price target of $2.00.
Keros Therapeutics (KROS)
In a report released today, Srikripa Devarakonda from Truist Financial assigned a Buy rating to Keros Therapeutics. The company’s shares closed last Tuesday at $66.11, close to its 52-week high of $73.00.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
Currently, the analyst consensus on Keros Therapeutics is a Strong Buy with an average price target of $84.25, representing a 25.2% upside. In a report issued on March 17, Leerink Partners also maintained a Buy rating on the stock with a $85.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price target of $105.00. The company’s shares closed yesterday at